Drug updated on 10/23/2023
|Injection (intravenous: 1 mg per 2 mL (0.5 mg per mL))
| Ongoing and
- For the treatment of metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting
- For the treatment of unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Product Monograph / Prescribing Information
|Halaven (eribulin mesylate) Prescribing Information.
|Eisai Inc. Nutley, NJ
Systematic Reviews / Meta-Analyses
|Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.
|Clinical Reviews in Oncology/Hematology